Table 2 Median PFS, OS, ORR and DCR on EGFR-TKI treatment in advanced-stage NSCLC patients with classic EGFR mutations

From: Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

 

N

Months

(95% CI)

P- value

Median PFS

All patients

98a

12.2

(10.8–13.5)

 

Exon 19

75

12.6

(11.2–14.1)

0.26

Exon 21

23

12.0

(7.5–16.6)

 

Median OS

All patients

107b

26.4

(22.8–30.1)

 

Exon 19

79

28.2

(21.8–34.6)

0.04

Exon 21

28

21.0

(20.4–21.6)

 
 

N

%

 

P- value

ORR

All patients

94c

84.0%

  

Exon 19

70

84.3%

 

0.91

Exon 21

24

83.3%

  

DCR

All patients

94c

95.7%

  

Exon 19

70

97.1%

 

0.25

Exon 21

24

91.7%

  
  1. Abbreviations: CI=confidence interval; DCR=disease control rate; EGFR=epidermal growth factor receptor; NSCLC=non-small-cell lung cancer; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; TKI=tyrosine kinase inhibitor.
  2. aFor 13 patients, data on PFS on EGFR-TKI treatment were incomplete (Supplementary Table 2).
  3. bFor 4 patients, data on OS on EGFR-TKI treatment were incomplete (Supplementary Table 3).
  4. cFor 17, patients data on response on EGFR-TKI treatment were incomplete (Supplementary Table 4).
Back to article page